Sermorelin + Ipamorelin Blend – Product Information
Sermorelin and Ipamorelin are both synthetic peptides known for their potential to stimulate the release of growth hormone (GH) from the pituitary gland. When studied together, Sermorelin and Ipamorelin may exhibit synergistic effects and enhance their individual actions on GH release.
Sermorelin, as a GHRH analog, works to stimulate the release of GH from the pituitary gland, while Ipamorelin, as a GHRP, potentially enhances the release of GH by directly targeting the receptors. This combination may result in a synergistic increase in GH secretion, potentially, if research is proven, may lead to enhanced anabolic effects, muscle growth, improved body composition, and other related physiological benefits.
It is important to note that studies with these peptides should strictly adhere to applicable regulations and ethical guidelines, and they should only be used for research purposes.
- Sermorelin + Ipamorelin Blend consists of two compounds: Sermorelin and Ipamorelin.
- Sermorelin + Ipamorelin Blend contains 5mg of Sermorelin and 5mg of Ipamorelin, totaling 10mg.
Sermorelin is a growth hormone-releasing hormone (GHRH) analog currently used in a clinical setting to evaluate growth hormone secretion. It is of interest to researchers for its potential ability to improve bone density, diminish scarring, combat the effects of dementia, and reduce seizure activity.
|Molar Mass||3357.93 g·mol−1|
Ipamorelin is a pentapeptide, which displays high GH-releasing potency and efficacy in vitro and in vivo. Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that shown by GHRH. The specificity of Ipamorelin makes this compound a very interesting candidate for future clinical development.
|Molar Mass||711.868 g·mol−1|